02 May 2003
PARP inhibition is therapeutic in CNS inflammation through immunomodulation
D. Hooper, R. Kean, T. Mikheeva, J. Mabley, C. Szabo, G. ScottMed Sci Monit 2003; 9(1): 28-0 :: ID: 15080
Abstract
We have used a novel phenathridinone PARP inhibitor, PJ-34, to probe the contribution of PARP to the pathogenesis of the multiple sclerosis model, experimental allergic encephalomyelitis (EAE). PJ-34 administration to mice immunized with myelin basic protein (MBP) significantly reduced the incidence of the disease as well as delayed the onset and reduced the severity of clinical signs of EAE in the treated mice that became sick. The loss of blood-brain barrier (BBB) integrity that facilitates immune/inflammatory cell invasion into central nervous system (CNS) tissues in EAE was inhibited by PJ-34, as was T cell infiltration into the CNS. On the other hand, the accumulation of activated monocytes in the CNS was only partly inhibited in PJ-34-treated mice that remained healthy and similar to that of diseased controls in mice where treatment was less effective. Similar patterns were seen for the expression of TNF-a, ICAM-1, IFN-g, and iNOS in CNS tissues in that PJ-34-treated mice with EAE resembled sick controls and treated mice that remained healthy were comparable to normal mice. While PJ-34 did not affect MBP-specific T cell proliferation in vitro, the proliferative response of T cells from PJ-34-treated mice immunized with MBP was reduced. The isotype profile of the antigen-specific antibodies elicited by MBP immunization was also altered, from predominantly IgG2a to IgG1 and IgG2b, by PJ-34 treatment. These results indicate that PARP inhibition is therapeutic in EAE by changing the bias of the response to MBP from pathogenic Th1-associated CNS inflammation to a Th-2 dependent humoral response.
Keywords: CNS, MS/EAE, T cells
Editorial
01 April 2025 : Editorial
Editorial: Rapid Testing for the Avian Influenza A(H5N1) Virus is Urgently Required as Infections in Poultry and Dairy Cows are on the Rise, and so is Transmission to HumansDOI: 10.12659/MSM.949109
Med Sci Monit 2025; 31:e949109
In Press
Clinical Research
Impact of Depression, Fatigue, and Pain on Quality of Life in Slovak Multiple Sclerosis PatientsMed Sci Monit In Press; DOI: 10.12659/MSM.947630
Clinical Research
Longitudinal Evaluation of Metabolic Benefits of Inactivated COVID-19 Vaccination in Diabetic Patients in T...Med Sci Monit In Press; DOI: 10.12659/MSM.947450
Clinical Research
Impact of Voltage Level on Hospitalization and Mortality in Electrical Injury Cases: A Retrospective Analys...Med Sci Monit In Press; DOI: 10.12659/MSM.947675
Clinical Research
Comparative Study of Plantar Load and Foot Posture Characteristics in Male Elite Squash Players and Non-Ath...Med Sci Monit In Press; DOI: 10.12659/MSM.947828
Most Viewed Current Articles
17 Jan 2024 : Review article 8,044,083
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,972
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 30,118
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 24,024
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912